Clinical Trial Update: Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pembrolizumab with or without vorinostat and tamoxifen for estrogen receptor-positive breast cancer; trial terminated with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tamoxifen (tamoxifen)
• Vorinostat (vorinostat)

Snippet

Sponsor: University of California, San Francisco | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8 | Phase 2 | Status: TERMINATED | Results posted: 2023-08-31